Skip to content
DataLookout
Menu

PRODARTNCT06822491

Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Primary completion date changed from estimate of Jun 2026 to Oct 30, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v3
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Multiparametric magnetic resonance imaging local control of the dominant intraprostatic lesion
Timeframe: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
Correlation of early prostate-specific antigen response with early multiparametric magnetic resonance imaging changes
Timeframe: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

Secondary (5)

Correlation of late prostate-specific antigen response with early multiparametric magnetic resonance imaging changes
Correlation of genitourinary and gastrointestinal toxicity with early multiparametric magnetic resonance imaging changes
Correlation of prostate quality of life with early multiparametric magnetic resonance imaging changes
To evaluate prostate volume change during and after adaptive prostate SBRT and to correlate to treatment toxicity.
Exploratory image analysis

Sites

1 site in 1 country

  • University Hospital ZurichZurich, Switzerland